Get the Stockscreener App
9.02
4.25%
-0.40
After Hours:
9.05
0.03
+0.33%
Anika Therapeutics Inc stock is traded at $9.02, with a volume of 112.31K.
It is down -4.25% in the last 24 hours and up +7.38% over the past month.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
See More
Previous Close:
$9.42
Open:
$9.45
24h Volume:
112.31K
Relative Volume:
0.94
Market Cap:
$130.05M
Revenue:
$166.88M
Net Income/Loss:
$-74.18M
P/E Ratio:
-1.7791
EPS:
-5.07
Net Cash Flow:
$1.14M
1W Performance:
-0.55%
1M Performance:
+7.38%
6M Performance:
-33.68%
1Y Performance:
-64.28%
1-Day Range:
$9.00
$9.465
1-Week Range:
$9.00
$9.58
52-Week Range:
$7.8701
$25.65
Anika Therapeutics Inc Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc
Sector
Phone
(781) 457-9000
Address
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
9.02 | 135.82M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | B. Riley Securities | Buy |
| Nov-01-24 | Reiterated | Barrington Research | Outperform |
| Aug-14-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-14-22 | Resumed | Stephens | Equal-Weight |
| Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-16-21 | Initiated | Stephens | Overweight |
| Jul-16-21 | Initiated | UBS | Neutral |
| Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
| Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Nov-05-19 | Initiated | BWS Financial | Sell |
| Sep-24-19 | Reiterated | Barrington Research | Outperform |
| Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
| Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
| Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Oct-27-17 | Reiterated | Barrington Research | Outperform |
| May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
| Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc Stock (ANIK) Latest News
Anika Therapeutics Inc. stock trend outlook and recovery path2025 Short Interest & Community Consensus Picks - newser.com
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire
United States Adhesion Barrier Market Set for Explosive Growth: - openPR.com
Can Anika Therapeutics Inc. (AKP) stock sustain double digit ROEJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
Weiss Ratings Reiterates "Sell (E+)" Rating for Anika Therapeutics (NASDAQ:ANIK) - MarketBeat
Orthopedic Digit Implants Market Report 2025-2033, with Profiles of Extremity Medical, Stryker, Zimmer, Smith & Nephew, Depuy, Arthrex, Acumed, Anika Therapeutics, VILEX, and Paragon 28 - Ortho Spine News
Orthopedic Digit Implants Market Report 2025-2033, with - GlobeNewswire
What technical models suggest about Anika Therapeutics Inc.’s comebackM&A Rumor & Stock Portfolio Risk Control - newser.com
Published on: 2025-10-05 06:33:40 - newser.com
Predicting Anika Therapeutics Inc. trend using moving averagesJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Anika Therapeutics Inc. stock trendline breakdownEarnings Recap Report & Fast Gaining Stock Reports - newser.com
Trend analysis for Anika Therapeutics Inc. this weekFed Meeting & Risk Managed Investment Entry Signals - newser.com
Leading vs lagging indicators on Anika Therapeutics Inc. performanceM&A Rumor & Real-Time Sentiment Analysis - newser.com
Analyzing Anika Therapeutics Inc. with multi timeframe chartsMarket Sentiment Report & Community Verified Trade Alerts - newser.com
Is Anika Therapeutics Inc. (AKP) stock attractive for growth fundsRisk Management & Real-Time Chart Breakout Alerts - newser.com
Using data filters to optimize entry into Anika Therapeutics Inc.New Guidance & High Conviction Investment Ideas - newser.com
Multi factor analysis applied to Anika Therapeutics Inc.M&A Rumor & Safe Investment Capital Preservation Plans - newser.com
Published on: 2025-10-03 01:07:01 - newser.com
How to monitor Anika Therapeutics Inc. with trend dashboardsEarnings Trend Report & High Conviction Investment Ideas - newser.com
What analysts say about Anika Therapeutics Inc stockMean Reversion Trades & Big Gains Small Investment - earlytimes.in
Can T I Global Limited Survive Disruption in Its Core IndustryRSI Overbought/Oversold & Double Digit Trading Ideas - earlytimes.in
What drives Anika Therapeutics Inc stock priceVolume Spike Alerts & Investment Recommendations You Can Trust - earlytimes.in
Published on: 2025-10-03 05:32:20 - earlytimes.in
Is Anika Therapeutics Inc AKP a good long term investmentPortfolio Diversification Tips & Capital Allocation Recommendations - earlytimes.in
Published on: 2025-09-27 05:01:43 - newser.com
What analysts say about Anika Therapeutics Inc AKP stockStop Loss Placement Tips & Exceptional Return Opportunities - Early Times
ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Anika Therapeutics Inc. $ANIK Stock Position Reduced by Goldman Sachs Group Inc. - Defense World
Barrington Research Reiterates "Outperform" Rating for Anika Therapeutics (NASDAQ:ANIK) - MarketBeat
Anika Therapeutics (ANIK) Rating Maintained with $15 Target by B - GuruFocus
Will Anika Therapeutics Inc. stock go up soonJuly 2025 Snapshot & Stock Portfolio Risk Control - newser.com
Barrington Maintains Anika Therapeutics(ANIK.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Anika Therapeutics Inc Stock (ANIK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anika Therapeutics Inc Stock (ANIK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
1.54%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):